About Us
50 Years' Combined Experience
Physical Longevity’s clinical team has over 50 years’ combined experience vetting and implementing cell therapies. Our nonsurgical orthopedic treatments use Mesenchymal Stem Cells (MSCs). Research shows that MSCs have the potential to naturally alleviate inflammation and pain. Our advanced protocols are applied to orthopedic injuries and conditions.
Physical Longevity sources its Mesenchymal Stem Cells from Cellcolabs in Sweden. Cellcolabs represents the highest stem cell-manufacturing standards around the globe, the result of over 20 years of MSC research. This leading-edge work was conducted by Professor Katarina Le Blanc at one of the foremost medical universities in the world, the Karolinska Institute in Sweden. Professor Le Blanc’s work includes 167 published scientific papers with over 30,000 citations.
Cellcolabs' cells are quality-controlled according to the International Society for Cell and Gene Therapy guidelines. The manufacturing is approved by the Swedish Medical Product Agency (The MPA). The cultivation of the cells takes place in a state-of-the-art GMP (Good Manufacturing Practice) facility next to the Karolinska Institute in Stockholm, Sweden.
With their gold standard protocols, Cellcolabs' Mesenchymal Stem Cells are carefully isolated and cultured to specific doses of up to 100,000,000 MSCs. This is exponentially higher than the doses available in the United States. In combination with Cellcolabs' stringent donor criteria, it’s likely that these cultivated stem cells are stronger than those harvested directly from our patients. As an added benefit, Physical Longevity's MSC procedures are one-step same-day treatments that do not involve the discomfort and inconvenience of blood draws or bone marrow drilling.
Musculoskeletal Injury Clinical Trial
Physical Longevity is part of a clinical trial to study Mesenchymal Stem Cells in musculoskeletal injuries. The trial is in partnership with Cellcolabs’ subsidiary, Cellcolabs Clinical. It has approval from the Bahamas National Stem Cell Ethics Committee.
Musculoskeletal injuries and degeneration can stem from sports-related injuries, biomechanics, and genetic predispositions. By evaluating the efficacy of MSCs in clinical trials for musculoskeletal injuries, we hope to observe an improvement in vitality that enables treated patients to access more active lifestyles as they age.
As with most other stem cell products, these are classified as an investigational medicinal product and do not yet have market approval. The clinical trials conducted by Physical Longevity in partnership with Cellcolabs Clinical are therefore necessary to provide more scientific data. Cellcolabs Clinical supports this work through driving scale in both academic research and its own clinical trials.